

REMARKS

As requested in the Notice to Comply, mailed May 17, 2002, Applicants are submitting a Sequence Listing and have amended the specification to insert the sequence identifiers. Thus, the specification is now in full compliance with 37 C.F.R. § 1.821.

The Commissioner is hereby authorized to charge any additional fees under 37 CFR §§ 1.16, 1.17 and 1.21 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 502082.

Date: 6/21/02

Respectfully submitted:

By: M. Christina Thomson

M. Christina Thomson, J.D.

Registration No. 43,190

KNOBBE MARTENS OLSON & BEAR LLP
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
Telephone: (949) 760-0404
Facsimile: (949) 760-9502

Version with markings to show changes made

The paragraph beginning on page 16, line 20 has been amended as follows:

The accessory function vector pLadeno5 was constructed as follows: DNA fragments encoding the E2a, E4, and VA RNA regions isolated from purified adenovirus serotype-2 DNA (obtained from Gibco BRL) were ligated into a plasmid called pAmpscript. The pAmpscript plasmid was assembled as follows: oligonucleotide-directed mutagenesis was used to eliminate a 623-bp region including the polylinker and alpha complementation expression cassette from pBSII s k+ (obtained from Stratagene), and replaced with an EcoRV site. The sequence of the mutagenic oligo used on the oligonucleotide-directed mutagenesis was 5'-CCGCTACAGGGCGCGATATCAGCTCACTCAA-3' (SEQ ID NO:1). A polylinker (containing the following restriction sites: Bam HI; KpnI; SrfI; XbaI; ClaI; BstI107I; Sall; PmeI; and NdeI) was synthesized and inserted into the EcoRV site created above such that the BamHI side of the linker was proximal to the fl origin in the modified plasmid to provide the pAmpscript plasmid. The sequence of the polylinker was 5'-GGATCCGGTACCGCCCGGGCTCTAGAATCGATGTATACGTCGACGTTTAAACCATATG-3' (SEQ ID NO:2).

The paragraph beginning on page 17, line 10 has been amended as follows:

The DNA comprising the adenovirus serotype-2 E4 sequences had to be modified before it could be inserted into the pAmpscript polylinker. Specifically, PCR mutagenesis was used to replace the E4 proximal, adenoviral terminal repeat with a SrfI site. The location of this SrfI site is equivalent to base pairs 35,836-35,844 of the adenovirus serotype-2 genome. The sequences of the oligonucleotides used in the mutagenesis were: 5'-AGAGGCCCGGGCGTTTTAGGGCGGAGTAACTTGC-3' (SEQ ID NO:3) and 5'-ACATACCCGCAGGCGTAGAGAC-3' (SEQ ID NO:4). A 3,192 bp E4 fragment, produced by cleaving the above-described modified E4 gene with SrfI and SpeI, was ligated between the SrfI and XbaI sites of pAmpscript which already contained the E2a and VA RNA sequences to result in the pLadeno5 plasmid. The 3,192-bp fragment is equivalent to base pairs 32,644-35,836 of the adenovirus serotype-2 genome.